Marker Therapeutics Secures $13.1M Grant To Support MultiTAA Cell Therapy Trial

Marker Therapeutics Inc MRKR received notice of a Product Development Research award of approximately $13.1 million from Texas's Cancer Prevention and Research Institute (CPRIT).
The CPRIT award is intended to support the adjuvant arm Phase 2 trial of its MultiTAA-specific T cell product MT-401 when given as an adjuvant therapy to patients with acute myeloid leukemia (AML) following a hematopoietic stem cell transplant.
The primary objectives of the adjuvant arm of the trial are to evaluate relapse-free survival compared with a randomized control group.
Price Action: MRKR shares are up are 15.50% at $1.94 during the premarket session on the last check Friday.